Gujarat Themis Biosyn Ltd · NSE:GUJTHEM
Gujarat Themis Biosyn — Q2 FY22 Earnings Presentation
30 slides from Gujarat Themis Biosyn's earnings presentation, Nov 15, 2021
Slide 1: Cover letter to BSE: Investor Presentation
0 GUJARAT THEMIS BIOSYN LIMITED CIN: L24230GJ1981PLC004878 L2423OGJ1 981 PLCOO4878 REGD. OFFICE REGD. OFFICE &FACTORY &FACTORY :: 69/C 69/0 GIDC GIDC INDUSTRIAL INDUSTRIAL ESTATE, ESTATE, VAPI—396195, VAPI DIST. VALSAD, – 396 195, DIST. VALSAD, GUJARAT, GUJARAT, INDIA INDIA TEL :: 0260 TEL 0260-2430
Slide 2: Gujarat Themis Biosyn Limited Investor Presentation Q2 & H1 FY22
Gujarat Themis Biosyn Limited Investor Presentation Q2 & H1 FY22
Slide 3: Disclaimer
: 3 to Click Disclaimer edit Master title style Disclaimer ] This presentation has been prepared by Gujarat Themis Biosyn Limited (the “Company” ”Company” or “GTBL”) ”GTBL”) solely for for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe f
Slide 4: Table of Contents
(A) Click to editofMaster Table title style Contents 0 Company Overview Business Overview O O Industry Overview Financial Highlights (0 Way Ahead Way Ahead 3
Slide 5: Company Overview
"-:Mi% ' 1 " < Company Overview >
Slide 6: Among India's few fermentation based intermediate manufacturers
Click Among to editIndia’s Master fewtitle style Fermentation based Intermediate manufacturer GTBL among one of India’s few fermentation based manufacturer in pharmaceutical field State of Art Manufacturing Facility ▪I Incorporated in 1981 as asjoint joint ▪ Plant in Vapi (Gujarat) sector Company wi
Slide 7: Journey So Far
Click to edit Master Journey So Fartitle style ] ▪I BIFR BIFR declared declared GTBL as sick Sl ▪. Repaid Repaid total total Company . . ' ▪- Established ' ' working ca Ital workln capital Established as joint as JOIht ▪I Dr. Dr. Dinesh Dinesh Patel Patel stepped stepped in in as as g p ▪I Productio
Slide 8: Expert and Experienced Management Team
Click to edit Master Expert title style Management Team and Experienced Dr. Dinesh Patel Dr. Sachin Patel Chairman Director ▪ Doctorate in Medicinal Chemistry UK. ▪ Member of Royal Society of Chemistry, London, U.K. ▪I Doctorate in Biological chemistry from Christ's College, ▪ Industrialist having m
Slide 9: Key Strengths
0 to Click Key Strengths edit Key Master title style Strengths Strong Product Portfolio ▪I Demand side remains strong for product manufactured 01 by GTBL by GTBL ▪I More than decade old products with no replacement for these ▪I Continued to be most accepted and preferred products Investments in R&D
Slide 10: Business Overview
Business Overview
Slide 11: Strong Product Portfolio - Growing at pace
Click toStrong edit Master & Nichetitle style Portfolio —– Growing at pace Product ] Current Product Portfolio Rifamycin . ' ----------------- ~ An intermediate lamyCIn ▪. An for ‘\ intermediate for / 1’ _______________ _ . Rifamycin - . Identified and ▪ Identified ' . developing four working develo
Slide 12: Advantages of using the Unique Fermentation Process
0 to Click Advantages of using edit Master title the styleUnique Fermentation Process ] L Fermentation Process Fermentation Fermentation Broth Solid // Liquid Solid Liduid Lab Filtration Separation GTBL and Fermentation Technology Technology - Strive to to develop new fermentation culture: ▪ Ferment
Slide 13: State of Art Manufacturing Facilities at Vapi
0 to Click State ofMaster editof State Art Manufacturing Art Manufacturing title style Facilities at Facilities at Vapi Vapi l l :allli Among very few companies in India with fermentation capabilities for for Intermediates Environment Friendly Environment Friendly & & Sustainable Sustainable Process
Slide 14: Industry Overview
Industry Overview *-
Slide 15: Pharmaceutical Market - An Overview
Click to edit Master title Pharmaceutical style An Overview Market- ] L q.01 Active Pharmaceutical Ingredient Market valued at 4.: North America-expected to dominate Active USD 172.69 Billion in 2018 and expected to reach Global Market O) 02 a: h USD Billion by 263.80 Billion USD 263.80 2025 with by
Slide 16: The Indian Pharma Advantage
‘: I to Click The Indi edit The an Pharma Phatitle Master Indian rma style Adv antage Advantage ] L ▪I Low cost of production & R&D boosts efficiency of Indian pharma companies, leading to competitive exports Cost Efficiency 01 ▪I India’s cost of production is approximately 33 per cent lower than th
Slide 17: Q2 & H1 FY22 Financial Highlights
_ x: _.. ..—_—_'_ -. L . (m _. I _. W Q2 & H1 FY22 Financial FY22 Financial Highlights \ I" 1 ‘I.
Slide 18: Management Comment
Click to edit Master Comment Management title style ] _ __________________ ~ ~~~~~ x ~‘ a’ s ’ Commenting on am pleased ”I am “I to share pleased to that our share that performance for financial performance our financial 02 FY22 for Q2 is continuation FY22 is of continuation of the Company the perfo
Slide 19: Q2 FY22 Financial Highlights
Click to Q2edit FY22Master titleHighlights Financial style Revenue (Rs. Cr) 32.44 35.05 27.20 27.20 24.40 23.30 23.30 15.66 15.66 I Q1 FY21 Q1 FY21 Q2 FY21 Q2 FY21 Q3 FY21 FY21 Q4 FY21 Q1 FY22 Q2 FY22 EBITDA excluding other income (Rs. Cr) / Margin (%) PAT (Rs. Cr) // Margin (%) 20 20 54.21% 54.21%
Slide 20: Q2 FY22 Financial Highlights
Click to Q2edit FY22Master titleHighlights Financial style Rs. Crs Q2 FY22 Q2 FY21 YoY% Q1 FY22 -..'n.99rn9.fr9m.9.9991905.. . . . . . . . . . . : Income from Operations 35.05 ...I 27.20 .......................... 32.44 ’———————————————————————————————————~ ‘————————————————————————————————————’ ...
Slide 21: H1 FY22 Financial Highlights
Click to FY2Master H1edit FY222 Financial Financia title style l Highlights Hig hlights ] 68 Rs. Crs H1 FY22 H1 FY22 H1 FY21 H1 FY21 YoY% /‘ —————————————————— ~~ ”“1899118nf19111998.181.191.18. Income from Operations . . . . . . . . . . . . . . . . . . . . . . . . . i.. . . . . . . . . . 67.49 87.7
Slide 22: Annual Financial Highlights
Annual Financial Highlights 1
Slide 23: Financial Highlights - FY21 vs FY20
i 0 Financial Click to Highlights edit Master Financial — FY21 vs title style Highlights – FY21 vs FY20 FY20 A a A ’a‘A A a A 6.39% I 6.39% I 26.67% I 713 bps Revenue from Operations EBITDA (excluding other income) EBITDA Margin Rs. 90.56 Crore Rs. 40.33 Crore 44.53% A ’a‘ A E A a A I 27.48% 27.48%
Slide 24: Annual Financial Highlights - FY21
Click to edit Master Annual title Financial style Highlights — – FY21 Revenue (Rs. Cr) SMLSG 90.56 85.12 381M) 38.80 41u05 41.05 35.69 FY17 FY18 FY19 FY20 FY21 EBITDA excluding other income (Rs. Cr) / Margin (%) Cr)// Margin (%) PAT (Rs. Cr) 45 45 44£36 44.5% 50% 50% 37JB6 37.4% 45% 33.3% 40 40 45%
Slide 25: Key Ratios
: 3 to Click Key Ratios edit Key Master title style Ratios RoCE(%[* RoCE(%)* RoA(%Q* * RoA(%)** 37.0% 70.91% 70.91% \ 34.2% \59.9% 59.9% 42.77% 41.40% 41.40% 20-4% 20.4% 18.9% 18.9% 19.6? 19.6% — \33-94 0 33.94% § — FY17 FY18 FY19 FY20 FY21 FY17 FY18 FY19 FY20 FY21 RoEl%|*** RoE(%)*** 53.3% 56.1% Vz
Slide 26: Annual Financial Highlights - FY21
0 to Click edit Master Annual title Financial style Highlights — – FY21 Rs. Crs FY21 FY20 YoY% IncomefromOPe—rat'ons:.. . . . . . . . 90.56 Income from Operations 9056.. . . . . . . . I . . . . . . . . . . .85.12 85....12.. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ot
Slide 27: Balance Sheet Highlights - As on 30th September 2021
i' 3 to Click Balance edit Master Balance title style—– As on 30 Sheet Highlights 30th th September 2021 Rs. Cr. Rs. Cr. Sept2021 Sept 2021 Mar 2021 Sept2021 Sept 2021 Mar 2021 Total Equity & Liabilities Total Assets Shareholders Funds 96.65 69.95 Non Current Non Current Assets Assets 37,45 37.46 24
Slide 28: Way Ahead
c 7 Way Ahead
Slide 29: Our Way Ahead
A to Click Our Way edit Our Ahead Master Way Aheadtitle style ] 68 ▪I In process of identifying new products which have good good domestic and export New Product Development & potential ▪I Company working on strategy to to move up the the value value chain by way way of forward forward Forward Integ
Slide 30: Thank You
0 to Click edit You Thank Master title style ] 68 For further information, please contact: Company:: Company Investor Relations Advisors : Gujarat Themis Biosyn Limited Bridge Investor Relations Pvt. Ltd. lyer Mr. Sangameshwar Iyer Mr. Amit Sharma - 9867726686 . . . Mr. Rahul Trivedi - 9833541841 Sa
Gujarat Themis Biosyn — Q2 FY22 Earnings Presentation on 6ix